Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05938010 · ClinicalTrials.gov registry record
Subjective Wearing Experience of the Total30 for Astigmatism Lens Among Satisfied Biofinity Toric Lens Wearers
A clinical trial, sponsored by Scripps Poway Eyecare and Optometry.
- Completed
- Registry status
- 42
- Enrollment target
NCT05938010: Completed study, sponsored by Scripps Poway Eyecare and Optometry.
NCT05938010 is a clinical trial that has completed, run by Scripps Poway Eyecare and Optometry. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05938010 has completed, sponsored by Scripps Poway Eyecare and Optometry.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
To subjectively evaluate wearing experience in the T30fA lens among subjects who were already satisfied with their Biofinity Toric lenses.
Primary Outcome
Subjects will give a rating between 0 and 10 (with 0 indicating not satisfactory at all and 10 indicating extremely satisfactory) best describing their comfort.
Interventions
- DEVICE Dailies Total1® contact lenses for astigmatism (T30fA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-07-25 |
| Est. Completion | 2023-09-26 |
What the finished NCT05938010 record still lists
NCT05938010 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Dailies Total1® contact lenses for astigmatism (T30fA) is the first listed.
NCT05938010 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05938010 about?
NCT05938010 is a clinical study titled "Subjective Wearing Experience of the Total30 for Astigmatism Lens Among Satisfied Biofinity Toric Lens Wearers". To subjectively evaluate wearing experience in the T30fA lens among subjects who were already satisfied with their Biofinity Toric lenses.
What is the current status of trial NCT05938010?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2023-07-25. Estimated completion is 2023-09-26.
What interventions are being tested in trial NCT05938010?
The interventions under investigation include: Dailies Total1® contact lenses for astigmatism (T30fA) (DEVICE).
Who is sponsoring clinical trial NCT05938010?
This trial is sponsored by Scripps Poway Eyecare and Optometry, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI